Diagnostic and Prognostic Value of Circulating CircRNAs in Cancer
Overview
Affiliations
Cancer has been regarded as one of the leading causes of mortality worldwide. Diagnostic and prognostic biomarkers with high sensitivity and specificity for cancer play a crucial role in preventing or treating cancer. Circular RNAs (circRNAs), which hold great potential for the management of cancer patients due to their abundance, stable property, and high specificity in serum, plasma, and other body fluids, can be used as non-invasive and blood-based biomarkers in cancer diagnosis and prognosis. There are four types of circRNAs including exonic circRNAs (ecircRNA), intronic circRNAs, exon-intron circRNAs (EIciRNA), and intergenic circRNAs. CircRNAs can act as miRNA sponges, affect protein translation, interplay with RNA binding proteins, regulate protein recruitment, and modulate protein scaffolding and assembly. Therefore, the multifunctionalities of circRNAs make them ideal for detecting and predicting cancer. Indeed, circRNAs manifest high sensitivity and specificity in more than ten types of cancer. This review aims to consolidate the types and functions of circRNAs, as well as discuss the diagnostic and prognostic value of circulating circRNAs in cancer.
circFOXP1: a potential diagnostic and therapeutic target in human diseases.
Yi Q, Ouyang X, Zhong K, Chen Z, Zhu W, Zhu G Front Immunol. 2024; 15:1489378.
PMID: 39606233 PMC: 11599189. DOI: 10.3389/fimmu.2024.1489378.
The role of circular RNAs (circRNAs) as a prognostic factor in lung cancer: a meta-analysis.
Ahsan S, Win T, Aye S, Than N BMC Cancer. 2024; 24(1):988.
PMID: 39123167 PMC: 11316314. DOI: 10.1186/s12885-024-12704-w.
CircWHSC1 (CircNSD2): A Novel Circular RNA in Multiple Cancers.
Zhang X, Yuan Y, Wang X, Wang H, Zhang L, He J Clin Med Insights Oncol. 2024; 18:11795549241254781.
PMID: 38855031 PMC: 11159554. DOI: 10.1177/11795549241254781.
Payervand N, Pakravan K, Razmara E, Vinu K, Ghodsi S, Heshmati M Heliyon. 2024; 10(11):e31584.
PMID: 38828320 PMC: 11140710. DOI: 10.1016/j.heliyon.2024.e31584.
Xie J, Lu L, Zhang J, Li Q, Chen W Oncol Res. 2024; 32(3):529-544.
PMID: 38361751 PMC: 10865731. DOI: 10.32604/or.2023.031511.